Clinical Trials Logo

Carotid Artery Stenosis clinical trials

View clinical trials related to Carotid Artery Stenosis.

Filter by:

NCT ID: NCT03931161 Active, not recruiting - Clinical trials for Carotid Artery Stenosis

Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1)

EVOCAR-1
Start date: September 4, 2019
Phase: Phase 4
Study type: Interventional

This is a phase IV, randomised, placebo-controlled, double-blind, parallel group study to determine the effect of Evolocumab treatment on carotid plaque morphology and composition in asymptomatic patients with >50% carotid artery stenosis.

NCT ID: NCT03816202 Completed - Clinical trials for Carotid Artery Stenosis

Sundt™ Carotid Shunt Retrospective Post Market Clinical Follow-up Study (PMCF)

Start date: April 25, 2019
Phase:
Study type: Observational

The primary objective of this study is to retrospectively investigate the safety and efficacy of the Integra Sundt™ carotid shunt during endarterectomy procedures.

NCT ID: NCT03764306 Terminated - Stroke, Ischemic Clinical Trials

New Ischemic Cerebral Lesions After Endarterectomy vs. Stenting for the Treatment of Symptomatic Carotid Stenosis

CARECarotid
Start date: May 1, 2015
Phase: N/A
Study type: Interventional

Background and purpose. Even if periprocedural cerebral microembolism associated with carotid endarterectomy or stenting usually does not manifest as clinically overt stroke, neuropsychological disturbances resulting from these events represent an important clinical and socioeconomic problem. Still, it remains unclear whether the use proximal protection can lower the incidence of cerebral embolism associated with the treatment of carotid stenosis. Materials and methods. This was a prospective randomised single-centre study, which was aimed at comparison of surgical eversion endarterectomy with stenting under proximal protection in symptomatic patients. The investigators evaluated the incidence of new ischaemic lesions revealed by the diffusion-weighted magnetic resonance imaging 2-4 days after the treatment and neurologic events.

NCT ID: NCT03504228 Completed - Clinical trials for Carotid Artery Stenosis

Prospective Single Arm CAS - ROADSAVER Study

ROADSAVER
Start date: January 23, 2018
Phase:
Study type: Observational

Approximately 2000 patients eligible for elective treatment with a Carotid Stent according to hospital routine practice in centers across Europe will be enrolled in the study. The maximum number of patients enrolled at each site will be not limited. Follow-ups are scheduled at discharge, 30 days, and 1 year, as per local practice. Each patient will have follow-up contacts via hospital visit and/or telephone.

NCT ID: NCT03495830 Recruiting - Clinical trials for Carotid Artery Stenosis

Stratification of Patient With Carotid Disease

TAXINOMISIS
Start date: March 29, 2018
Phase:
Study type: Observational

Introduction: Taxinomisis trial is part of the Taxinomisis project. The concept of the Taxinomisis project is to stratify carotid artery disease relying on new modern data corresponding to contemporary patients based on information from longitudinal studies. Taxinomisis trial will validate this tool and adjust such stratification. Initial step of the project is characterization of symptomatic and asymptomatic carotid atherosclerotic plaque lesions, identification of risk and susceptibility factors through the exploitation of longitudinal cohort data and multiomics and disintegration of carotid artery disease phenotypes into endotypes through joint modeling of multipleomics data sets and systems medicine approaches. Finally such stratification model will be validated and adjusted in the Taxinomisis clinical trial.

NCT ID: NCT03464851 Terminated - Clinical trials for Carotid Artery Stenosis

Evaluation of a Novel Technique to Diagnose Carotid Artery Stenosis

Start date: March 8, 2018
Phase:
Study type: Observational

The purpose of this study is to determine the accuracy of a new non-invasive device, the Carotid Stenotic Scan (CSS), to check for stenosis of the internal carotid artery (ICA) as compared to a carotid ultrasound study.

NCT ID: NCT03353103 Recruiting - Clinical trials for Carotid Artery Stenosis

Imaging of Unstable Carotid Plaque in Patient Referred to Endarterectomy

CAROTEP
Start date: September 3, 2018
Phase: Phase 2
Study type: Interventional

This study will assess unstable plaque imaging features by using high resolution MR imaging and Sodium Fluoride F-18 PET. This is a comparative study between symptomatic and asymptomatic patient referred to carotid endateriectomy, with reference to pathologic analysis of plaque components

NCT ID: NCT03195673 Recruiting - Clinical trials for Carotid Artery Stenosis

Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting

TZ-CAS
Start date: March 2, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of low dosage of Terazosin in Carotid Artery Stenting

NCT ID: NCT03133429 Completed - Clinical trials for Carotid Artery Stenosis

Clinical Study to Evaluate the Safety and Effectiveness of MER® Stents in Carotid Revascularisation.

MER
Start date: October 2016
Phase: N/A
Study type: Interventional

The aim of the study is to confirm, whether the MER® stent can be used, without limitations, for the endovascular carotid stenosis treatment in daily clinical practice. Eligible patients will undergo the procedure of the common or internal carotid artery stenting using MER® with proximal or distal neuroprotection.

NCT ID: NCT03079115 Recruiting - Clinical trials for Carotid Artery Stenosis

High Dose Atorvastatin for Preventing Periprocedural Ischemic Brain Damage During Carotid Artery Stenting

PICAS
Start date: August 21, 2017
Phase: Phase 4
Study type: Interventional

The purpose is to test whether a short-term, high-dose atorvastatin treatment (80mg once a daily (QD) from 3 days before to 3 days after CAS, then 20 mg QD until 30 days after CAS) is superior to conventional-dose atorvastatin treatment (20 mg QD from 3 days before to 30 days after CAS), in terms of efficacy for prevention of periprocedural ischemic brain damage in Chinese patients undergoing CAS.